cyclobenzaprine vs nalbuphine
According to this portal's Publishing Organization, this page was last reviewed in August 2026 against our methodology. Figures and extracts on this site, including tables above 1,000 rows when the corpus is that large, are the publisher's responsibility.
Side-by-side comparison of cyclobenzaprine and nalbuphine. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
minor Known Drug Interaction
Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), and monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and...
Flexeril, Amrix
Nubain
Cyclobenzaprine is a muscle relaxant. It helps relieve muscle spasms and pain.
Nalbuphine injection is a strong pain medicine. It is used when other pain treatments don't work well enough.
This medicine treats muscle spasms caused by painful conditions. It is meant to be used with rest and physical therapy. It should only be used for a short time, usually 2 to 3 weeks.
Nalbuphine injection is used to manage severe pain that requires a strong opioid medicine. It can also be used before and after surgery to help with pain. It can also be used during labor and delivery for pain relief.
Cyclobenzaprine works in the brain and spinal cord to relax your muscles. It reduces muscle spasms, which helps to relieve pain and improve movement. It does not directly work on the muscles themselves.
Nalbuphine works by attaching to opioid receptors in the brain and spinal cord. These receptors help to block pain signals. Nalbuphine both activates and blocks opioid receptors.
- • Drowsiness
- • Dry mouth
- • Fatigue
- • Headache
- • Feeling sleepy
- • Sweaty or clammy skin
- • Nausea
- • Vomiting
- • Dizziness
- Pain 4,871
- Fatigue 3,808
- Nausea 3,303
- Headache 3,292
- Chronic Kidney Disease 2,749
- Drug Hypersensitivity 36
- Foetal Exposure During Pregnancy 10
- Neonatal Asphyxia 10
- Neonatal Epileptic Seizure 10
- Pain 7
You should not take this medicine if you are allergic to any of its ingredients. You should not take this medicine if you are taking a monoamine oxidase (MAO) inhibitor or have taken one in the past 14 days. Taking cyclobenzaprine with an MAO inhibitor can cause serious problems, including seizures and death. Also, do not take it if you have heart problems or an overactive thyroid.
Nalbuphine can cause serious breathing problems that can be life-threatening, especially when you first start taking it or after a dose increase. Taking nalbuphine with benzodiazepines (like anxiety or sleep medicines) or other drugs that can make you sleepy, including alcohol, can cause very serious sleepiness, breathing problems, coma, and death.
It is not known if cyclobenzaprine can harm an unborn baby. Talk to your doctor if you are pregnant, planning to become pregnant, or breastfeeding.
Using nalbuphine during pregnancy may cause breathing problems in the newborn. Talk to your doctor if you are pregnant or plan to become pregnant. It is not known if nalbuphine passes into breast milk. Talk to your doctor about the risks and benefits of breastfeeding.
Also Compare, Nearby Drugs
Compare cyclobenzaprine with
Compare nalbuphine with
How to Read This cyclobenzaprine vs nalbuphine Comparison
cyclobenzaprine is classified in the Muscle Relaxant drug class, while nalbuphine sits within the Opioid Agonist-Antagonist class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, cyclobenzaprine has 18,023 submissions while nalbuphine has 73. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known minor interaction flagged in FDA labeling, attributed to these medications both affect the serotonin system in your brain. using them together increases the risk of having too much serotonin in your body at once.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for cyclobenzaprine or nalbuphine.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.